Princeton-based Certara, announced on Tuesday it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.
CGH is a new product development innovation practice inspired by Certara’s drug development and scientific due diligence work for the Bill & Melinda Gates Foundation.
“Certara Global Health will bring together talent, technology, software, systems and processes to accelerate the development of medicines for those that need them most,” said Craig Rayner, senior vice president and co-lead of CGH, in a statement.
“Working closely with the foundation and other leaders in the global health sector, CGH will focus on creating novel and impactful drug development, regulatory science and patient access approaches that will deliver effective and affordable therapies to populations in need around the world. A triple bottom line practice across the global health product development ecosystem,” said Rayner.
“Developing medicines is expensive and difficult at the best of times, and securing talent and capital is an extra challenge for the global health sector,” said Kevin Hershberger, vice president and co-lead of CGH. “But we are confident that we can play a catalytic role in bringing creative thinkers together with leading-edge technologies and methodologies, to support solving medicine development and access challenges in global health,” said Hershberger.